An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results
JT Schiller, X Castellsagué, LL Villa, A Hildesheim - Vaccine, 2008 - Elsevier
This review focuses on recent publications of clinical trials of two prophylactic human
papillomavirus (HPV) vaccines: Gardasil®(Merck & Co., Inc., Whitehouse Station, NJ USA) …
papillomavirus (HPV) vaccines: Gardasil®(Merck & Co., Inc., Whitehouse Station, NJ USA) …
Clinical trials of human papillomavirus vaccines and beyond
M Lehtinen, J Dillner - Nature reviews Clinical oncology, 2013 - nature.com
Human papillomavirus (HPV) is the most common sexually transmitted infectious agent; its
14 oncogenic types are causally associated with 5–10% of all cancers. The major structural …
14 oncogenic types are causally associated with 5–10% of all cancers. The major structural …
[HTML][HTML] Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
Future II Study Group - New England Journal of Medicine, 2007 - Mass Medical Soc
Background Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause
approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate …
approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate …
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a …
EA Joura, S Leodolter, M Hernandez-Avila… - The Lancet, 2007 - thelancet.com
Background Vulval and vaginal cancers among younger women are often related to
infection with human papillomavirus (HPV). These cancers are preceded by high-grade …
infection with human papillomavirus (HPV). These cancers are preceded by high-grade …
Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of three cohorts from …
M Lehtinen, C Lagheden, T Luostarinen, T Eriksson… - BMJ open, 2017 - bmjopen.bmj.com
Objective Due to long lag time between infection/cancer diagnoses human papillomavirus
(HPV) vaccination programs will deliver vaccine efficacy (VE) estimates against cancer end …
(HPV) vaccination programs will deliver vaccine efficacy (VE) estimates against cancer end …
HPV vaccination for the prevention of cervical intraepithelial neoplasia
JA Kahn - New England Journal of Medicine, 2009 - Mass Medical Soc
A sexually active 18-year-old woman presents to her internist for an annual examination and
asks whether she should receive the human papillomavirus (HPV) vaccine. HPV causes …
asks whether she should receive the human papillomavirus (HPV) vaccine. HPV causes …
Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two …
FC Mariz, P Gray, N Bender, T Eriksson… - The Lancet Infectious …, 2021 - thelancet.com
Background Quadrivalent and bivalent vaccines against oncogenic human papillomavirus
(HPV) are used worldwide with different reported overall efficacies against HPV infections …
(HPV) are used worldwide with different reported overall efficacies against HPV infections …
Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial
M Lehtinen, C Lagheden, T Luostarinen, T Eriksson… - BMJ open, 2021 - bmjopen.bmj.com
Background Human papillomavirus (HPV) vaccination protects against HPV, a necessary
risk factor for cervical cancer. We now report results from population-based follow-up of …
risk factor for cervical cancer. We now report results from population-based follow-up of …
Anticipated acceptance of HPV vaccination at the baseline of implementation: a survey of parental and adolescent knowledge and attitudes in Finland
SC Woodhall, M Lehtinen, T Verho, H Huhtala… - Journal of Adolescent …, 2007 - Elsevier
We evaluated acceptance of human papillomavirus (HPV) vaccination by adolescents and
their parents, 83% and 86% of whom accepted vaccination. Improving knowledge and …
their parents, 83% and 86% of whom accepted vaccination. Improving knowledge and …
Eradication of human papillomavirus and elimination of HPV-related diseases–scientific basis for global public health policies
M Lehtinen, I Baussano, J Paavonen… - Expert review of …, 2019 - Taylor & Francis
Introduction: Infections with oncogenic human papillomaviruses (HPV) globally cause about
9% of cancers in females and 1% of cancers in males. HPV disease burden can be …
9% of cancers in females and 1% of cancers in males. HPV disease burden can be …